Increased creatine-kinase MB level after bypass surgery

Publication
Article
Cardiology Review® OnlineNovember 2007
Volume 24
Issue 11

A 72-year-old man presented with angina, dynamic ST-segment depression, and increased troponin and creatine kinase-myocardial band (CK-MB) levels above the institutional upper limits of normal (ULN).

A 72-year-old man presented with angina, dynamic ST-segment depression, and increased troponin and creatine kinase-myocardial band (CK-MB) levels above the institutional upper limits of normal (ULN). Initial medical therapy included aspirin, antithrombin therapy, beta blockers, angiotensin-converting enzyme (ACE) inhibitors, and glycoprotein IIb/IIIa inhibitors.

The patient underwent coronary angiography, which showed 3-vessel coronary artery disease. Three days later, he underwent coronary artery bypass graft (CABG) surgery with no complications. Prior to surgery, his CK-MB level had returned to normal, but when his CK-MB level was checked the day after surgery, it was 58 (ULN x 9). He had an uneventful postoperative course and was treated with aspirin, a beta blocker, an ACE inhibitor, and a statin. Based on the results of our study, the patient's increased post-CABG surgery CK-MB level was an independent predictor of worse mortality over the 6-month follow-up period. It is not yet known how to best treat patients specifically for CK-MB elevation, but prudent care would include aggressive secondary prevention. More research is needed to develop agents and strategies for myocardial preservation during CABG surgery.

Recent Videos
Brendon Neuen, MBBS, PhD | Credit: X.com
A panel of 5 cardiovascular experts
Video 5 - "Real-World Insights: Navigating Cardiac Myosin inhibitors in Practice" - Featuring 1 KOL
A panel of 5 cardiovascular experts
A panel of 5 cardiovascular experts
Video 4 - "Mavacamten in oHCM: Navigating the REMS Program for Safe, Optimal Outcomes "
Video 3 - "Aligning With 2023 ESC Guidelines in oHCM Treatment"
Robert Rosenson, MD | Credit: Cura Foundation
A panel of 5 cardiovascular experts
A panel of 5 cardiovascular experts
© 2024 MJH Life Sciences

All rights reserved.